Harvard Bioscience

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.

Earnings data Q1 2024

HBIO reports strong Q1 earnings, eyes growth in industrial segments

HBIO's Q1 performance reflects strong revenue growth, improved margins, and positive earnings. While facing challenges in revenue cadence and customer mix, the company is well-positioned to capitalize on opportunities in sales force reorganization and product demand.

HBIO reports Q2 revenue dip, eyes international growth opportunities

HBIO's Q2 2023 performance showed a slight decline in revenue but improved gross margin and operating profit. The company faces challenges in gross margin decline and slower U.S. sales, but new product introductions and international growth present opportunities for future expansion.

HBIO reports Q3 revenue decline but strong margin improvements

HBIO's Q3 performance showed mixed results with revenue decline but significant improvements in gross margin, adjusted EBITDA, and cash flow from operations. The company faces challenges in China and Asia Pacific due to reduced demand for respiratory products, but it anticipates maintaining strong margins and sees opportunities in new product offerings and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOLLISTON, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced a labor force reduction to improve its operating cost structure and support its ongoing investments in growth.

Harvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth

HOLLISTON, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, will be presenting to investors at the upcoming Sidoti Small Cap Conference and KeyBanc Life Sciences & MedTech Conference, both to be held virtually in March 2024. Joining him will be Jennifer Cote, the Company's Chief Financial Officer.

Harvard Bioscience, Inc. to Participate in March 2024 Investor Conferences: Sidoti's Small Cap Conference and KeyBanc's Life Sciences & MedTech Conference

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q4 2023 Earnings Conference Call March 7, 2024 8:00 AM ET Company Participants Dave Sirois - Director, SEC Reporting Jim Green - Chairman, President & Chief Executive Officer Jennifer Cote - Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc Frank DiLorenzo - Singular Research Operator Good morning, and thank you for standing by. Welcome to Harvard Bioscience, Inc. Fourth Quarter 2023 Earnings Conference Call.

Harvard Bioscience, Inc. (HBIO) Q4 2023 Earnings Call Transcript

HOLLISTON, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2023.

Harvard Bioscience Announces Fourth Quarter 2023 Financial Results

Solutions for CROs, pharma and biotechs improve throughput and efficiency and enable future advancements in data analytics Solutions for CROs, pharma and biotechs improve throughput and efficiency and enable future advancements in data analytics

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting

HOLLISTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2023 before the market opens on March 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call for March 7, 2024 at 8:00 AM ET

HOLLISTON, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced it will be presenting at the Benchmark Company 12th Annual Discovery One-on-One Investor Conference to be held Thursday December 7th, 2023 at the New York Athletic Club in New York City.

Harvard Bioscience to Present at Benchmark Company's Discovery One-On-One Investor Conference on December 7, 2023

HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present to investors at the Southwest IDEAS Investor Conference on Thursday November 16, 2023 at The Statler in Dallas, Texas. Joining him will be Jennifer Cote, the company's Chief Financial Officer and Treasurer.

Harvard Bioscience to Present at Southwest IDEAS Investor Conference on November 16, 2023

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Dave Sirois - Director, Corporate Accounting & SEC Reporting James Green - Chairman, President & Chief Executive Officer Jennifer Cote - Chief Financial Officer Conference Call Participants Bruce Jackson - The Benchmark Company Operator Thank you for standing by and welcome to the Harvard Biosciences Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded.

Harvard Bioscience, Inc. (HBIO) Q3 2023 Earnings Call Transcript

HOLLISTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter ended September 30, 2023.

Harvard Bioscience Announces Third Quarter 2023 Financial Results

HOLLISTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) conference from November 12-15, 2023, in Washington, D.C.

Harvard Bioscience to Showcase Latest Innovations in Preclinical and Organoid Research at Society for Neuroscience Conference on November 12-15, 2023

HOLLISTON, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2023 before the market opens on November 7, 2023, and will hold a conference call to discuss the results at 8:00 a.m.

Harvard Bioscience Schedules Third Quarter 2023 Earnings Conference Call for November 7, 2023 at 8:00 AM ET

Includes dedicated version for integration with Ponemah data management software from Data Sciences International (DSI)

Harvard Bioscience and Etisense Announce Agreement for Supply and Distribution of DECRO Miniature Telemetry Jacket Platform for Pre-Clinical Research

Harvard Bioscience's Q2 earnings showed a slight miss on EPS and revenue, causing a decline in the stock price. The company is committed to improving its product portfolio and has observed increased traction from new products launched last year. Despite the earnings miss, Harvard Bioscience is still pulling in profit and experiencing growth, with updated guidance for 2023 showing expected revenue increase.

Harvard Bioscience: Looking To Reload After Post-Q2 Earnings Sell-Off

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Dave Sirois - Director, Corporate Accounting & SEC Reporting James Green - Chairman, President & Chief Executive Officer Jennifer Cote - Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc Bruce Jackson - The Benchmark Company Operator Thank you for standing by and welcome to Harvard Bioscience's Second Quarter 2023 Earnings Call. [Operator Instructions] I would now like to hand the call over to your host, David Sirois, Director of SEC Reporting.

Harvard Bioscience, Inc. (HBIO) Q2 2023 Earnings Call Transcript

Harvard Bioscience (HBIO) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.05 per share a year ago.

Harvard Bioscience (HBIO) Q2 Earnings and Revenues Lag Estimates

HOLLISTON, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter ended June 30, 2023.

Harvard Bioscience Announces Second Quarter 2023 Financial Results

HOLLISTON, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present to investors at the Sidoti August Virtual Investor Conference on August 16, 2023. Joining him will be Jennifer Cote, the company's Chief Financial Officer and Treasurer.

Harvard Bioscience to Present at Sidoti Virtual Investor Conference on August 16, 2023

HOLLISTON, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2023 before the market opens on August 8, 2023, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Harvard Bioscience Schedules Second Quarter 2023 Earnings Conference Call for August 8, 2023 at 8:00 AM ET

HOLLISTON, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced that it is set to join the Russell 2000® and Russell 3000 Indexes, according to preliminary membership information posted to the FTSE Russell website. The addition is expected to become effective at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023.

Harvard Bioscience Set to Join Russell 2000® and 3000® Indexes

Harvard Bioscience (HBIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Here's Why Momentum in Harvard Bioscience (HBIO) Should Keep going

Today, we take our first look at medical device concern Harvard Bioscience, Inc. The shares have doubled over the past few months on better-than-expected results and improving cash flow. Can the rally continue? An investment analysis follows in the paragraphs below.

Harvard Bioscience: Rally In Shares Losing Steam

HOLLISTON, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of Jennifer Cote as the Company's Chief Financial Officer and Treasurer, effective June 19, 2023.

Harvard Bioscience Appoints Jennifer Cote as Chief Financial Officer

Mettler-Toledo

Waters

The Zacks Instruments - Scientific industry participants like Harvard Bioscience (HBIO), Mettler-Toledo (MTD) and Waters (WAT) are gaining from strong life science, pharmaceutical and academic end-market demand despite the challenging macroeconomic environment.

3 Instruments Stocks to Watch From a Prospering Industry

InterDigital

MicroStrategy Incorporated

Weave Communications

Investors should consider stocks like Harvard Bioscience (HBIO), MicroStrategy (MSTR), Meta Platforms (META), InterDigital (IDCC), and Weave Communications (WEAV) in their portfolio if they want to outperform the broader market.

News for Harvard Bioscience Stock (HBIO)